Petrov A

References (18)

Title : Luminescent nanoparticles for rapid monitoring of endogenous acetylcholine release in mice atria - Mukhametshina_2018_Luminescence_33_588
Author(s) : Mukhametshina A , Petrov A , Fedorenko S , Petrov KA , Nizameev I , Mustafina A , Sinyashin O
Ref : Luminescence , 33 :588 , 2018
Abstract : The present work introduces for the first time a nanoparticulate approach for ex vivo monitoring of acetylcholinesterase-catalyzed hydrolysis of endogenous acetylcholine released from nerve varicosities in mice atria. Amino-modified 20-nm size silica nanoparticles (SNs) doped by luminescent Tb(III) complexes were applied as the nanosensors. Their sensing capacity results from the decreased intensity of Tb(III)-centred luminescence due to the quenching effect of acetic acid derived from acetylcholinesterase-catalyzed hydrolysis of acetylcholine. Sensitivity of the SNs in monitoring acetylcholine hydrolysis was confirmed by in vitro experiments. Isolated atria were exposed to the nanosensors for 10 min to stain cell membranes. Acetylcholine hydrolysis was monitored optically in the atria samples by measuring quenching of Tb(III)-centred luminescence by acetic acid derived from endogenous acetylcholine due to its acetylcholinesterase-catalyzed hydrolysis. The reliability of the sensing was demonstrated by the quenching effect of exogenous acetylcholine added to the bath solution. Additionally, no luminescence quenching occurred when the atria were pre-treated with the acetylcholinesterase inhibitor paraoxon.
ESTHER : Mukhametshina_2018_Luminescence_33_588
PubMedSearch : Mukhametshina_2018_Luminescence_33_588
PubMedID: 29377578

Title : The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitors - Cox_2016_Bioorg.Med.Chem.Lett_26_2622
Author(s) : Cox JM , Chu HD , Kuethe JT , Gao YD , Scapin G , Eiermann G , He H , Li X , Lyons KA , Metzger J , Petrov A , Wu JK , Xu S , Sinha-Roy R , Weber AE , Biftu T
Ref : Bioorganic & Medicinal Chemistry Lett , 26 :2622 , 2016
Abstract : Novel potent and selective 5,6,5- and 5,5,6-tricyclic pyrrolidine dipeptidyl peptidase IV (DPP-4) inhibitors were identified. Structure-activity relationship (SAR) efforts focused on improving the intrinsic DPP-4 inhibition potency, increasing protease selectivity, and demonstrating clean ion channel and cytochrome P450 profiles while trying to achieve a pharmacokinetic profile suitable for once weekly dosing in humans.
ESTHER : Cox_2016_Bioorg.Med.Chem.Lett_26_2622
PubMedSearch : Cox_2016_Bioorg.Med.Chem.Lett_26_2622
PubMedID: 27106708
Gene_locus related to this paper: human-DPP4

Title : Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes - Biftu_2014_J.Med.Chem_57_3205
Author(s) : Biftu T , Sinha-Roy R , Chen P , Qian X , Feng D , Kuethe JT , Scapin G , Gao YD , Yan Y , Krueger D , Bak A , Eiermann G , He J , Cox J , Hicks J , Lyons K , He H , Salituro G , Tong S , Patel S , Doss G , Petrov A , Wu J , Xu SS , Sewall C , Zhang X , Zhang B , Thornberry NA , Weber AE
Ref : Journal of Medicinal Chemistry , 57 :3205 , 2014
Abstract : In our effort to discover DPP-4 inhibitors with added benefits over currently commercially available DPP-4 inhibitors, MK-3102 (omarigliptin), was identified as a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor with an excellent pharmacokinetic profile amenable for once-weekly human dosing and selected as a clinical development candidate. This manuscript summarizes the mechanism of action, scientific rationale, medicinal chemistry, pharmacokinetic properties, and human efficacy data for omarigliptin, which is currently in phase 3 clinical development.
ESTHER : Biftu_2014_J.Med.Chem_57_3205
PubMedSearch : Biftu_2014_J.Med.Chem_57_3205
PubMedID: 24660890
Gene_locus related to this paper: human-DPP4

Title : Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors - Edmondson_2009_Bioorg.Med.Chem.Lett_19_4097
Author(s) : Edmondson SD , Mastracchio A , Cox JM , Eiermann GJ , He H , Lyons KA , Patel RA , Patel SB , Petrov A , Scapin G , Wu JK , Xu S , Zhu B , Thornberry NA , Roy RS , Weber AE
Ref : Bioorganic & Medicinal Chemistry Lett , 19 :4097 , 2009
Abstract : A new series of DPP-4 inhibitors derived from piperidine-fused benzimidazoles and imidazopyridines is described. Optimization of this class of DPP-4 inhibitors led to the discovery of imidazopyridine 34. The potency, selectivity, cross-species DMPK profiles, and in vivo efficacy of 34 is reported.
ESTHER : Edmondson_2009_Bioorg.Med.Chem.Lett_19_4097
PubMedSearch : Edmondson_2009_Bioorg.Med.Chem.Lett_19_4097
PubMedID: 19539471
Gene_locus related to this paper: human-DPP4

Title : Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes - Mu_2009_Eur.J.Pharmacol_623_148
Author(s) : Mu J , Petrov A , Eiermann GJ , Woods J , Zhou YP , Li Z , Zycband E , Feng Y , Zhu L , Roy RS , Howard AD , Li C , Thornberry NA , Zhang BB
Ref : European Journal of Pharmacology , 623 :148 , 2009
Abstract : Inhibition of dipeptidyl peptidase-4 (DPP-4) activity has been shown to improve glycemic control in patients with type 2 diabetes by prolonging and potentiating the actions of incretin hormones. This study is designed to determine the effects of the DPP-4 inhibitor sitagliptin on improving islet function in a mouse model of insulin resistance and insulin secretion defects. ICR mice were pre-treated with high fat diet and a low dose of streptozotocin to induce insulin resistance and impaired insulin secretion, respectively. Diabetic mice were treated with sitagliptin or the sulfonylurea agent glipizide as admixture to high fat diet for ten weeks. Sustained reduction of blood glucose, HbA(1c), circulating glucagon and improvement in oral glucose tolerance were observed in mice treated with sitagliptin. In contrast, glipizide improved glycemic control only during the early weeks and to a lesser degree compared to sitagliptin, and had no effect on circulating glucagon levels or glucose tolerance. The improvement in glycemic control in sitagliptin-treated mice was associated with a significant increase in glucose-dependent insulin secretion in both perfused pancreas and isolated islets. Importantly, in contrast to the lack of effect by glipizide, sitagliptin significantly restored beta and alpha cell mass as well as alpha/beta cell ratio. These data indicate that DPP-4 inhibition by sitagliptin provided better overall improvement of glycemic control compared to glipizide in the high fat diet/streptozotocin induced diabetic mouse model. The ability of sitagliptin to enhance islet cell function may offer insight into the potential for disease modification.
ESTHER : Mu_2009_Eur.J.Pharmacol_623_148
PubMedSearch : Mu_2009_Eur.J.Pharmacol_623_148
PubMedID: 19765579

Title : Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines - Kim_2008_J.Med.Chem_51_589
Author(s) : Kim D , Kowalchick JE , Brockunier LL , Parmee ER , Eiermann GJ , Fisher MH , He H , Leiting B , Lyons K , Scapin G , Patel SB , Petrov A , Pryor KD , Roy RS , Wu JK , Zhang X , Wyvratt MJ , Zhang BB , Zhu L , Thornberry NA , Weber AE
Ref : Journal of Medicinal Chemistry , 51 :589 , 2008
Abstract : A series of beta-aminoamides bearing triazolopiperazines have been discovered as potent, selective, and orally active dipeptidyl peptidase IV (DPP-4) inhibitors by extensive structure-activity relationship (SAR) studies around the triazolopiperazine moiety. Among these, compound 34b with excellent in vitro potency (IC50 = 4.3 nM) against DPP-4, high selectivity over other enzymes, and good pharmacokinetic profiles exhibited pronounced in vivo efficacy in an oral glucose tolerance test (OGTT) in lean mice. On the basis of these properties, compound 34b has been profiled in detail. Further refinement of the triazolopiperazines resulted in the discovery of a series of extremely potent compounds with subnanomolar activity against DPP-4 (42b- 49b), that is, 4-fluorobenzyl-substituted compound 46b, which is notable for its superior potency (IC50 = 0.18 nM). X-ray crystal structure determination of compounds 34b and 46b in complex with DPP-4 enzyme revealed that (R)-stereochemistry at the 8-position of triazolopiperazines is strongly preferred over (S) with respect to DPP-4 inhibition.
ESTHER : Kim_2008_J.Med.Chem_51_589
PubMedSearch : Kim_2008_J.Med.Chem_51_589
PubMedID: 18201067

Title : (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)- 1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes - Biftu_2007_Bioorg.Med.Chem.Lett_17_49
Author(s) : Biftu T , Feng D , Qian X , Liang GB , Kieczykowski G , Eiermann G , He H , Leiting B , Lyons K , Petrov A , Sinha-Roy R , Zhang B , Scapin G , Patel S , Gao YD , Singh S , Wu J , Zhang X , Thornberry NA , Weber AE
Ref : Bioorganic & Medicinal Chemistry Lett , 17 :49 , 2007
Abstract : Replacement of the triazolopiperazine ring of sitagliptin (DPP-4 IC(50)=18nM) with 3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one gave dipeptidyl peptidase IV (DPP-4) inhibitor 1 which is potent (DPP-4 IC(50)=2.6nM), selective, and efficacious in an oral glucose tolerance test in mice. It was selected for extensive preclinical development as a potential back-up candidate to sitagliptin.
ESTHER : Biftu_2007_Bioorg.Med.Chem.Lett_17_49
PubMedSearch : Biftu_2007_Bioorg.Med.Chem.Lett_17_49
PubMedID: 17055272
Gene_locus related to this paper: human-DPP4

Title : Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin - Biftu_2007_Bioorg.Med.Chem.Lett_17_3384
Author(s) : Biftu T , Scapin G , Singh S , Feng D , Becker JW , Eiermann G , He H , Lyons K , Patel S , Petrov A , Sinha-Roy R , Zhang B , Wu J , Zhang X , Doss GA , Thornberry NA , Weber AE
Ref : Bioorganic & Medicinal Chemistry Lett , 17 :3384 , 2007
Abstract : Molecular modeling was used to design a rigid analog of sitagliptin 1. The X-ray crystal structure of sitagliptin bound to DPP-4 suggested that the central beta-amino butyl amide moiety could be replaced with a cyclohexylamine group. This was confirmed by structural analysis and the resulting analog 2a was synthesized and found to be a potent DPP-4 inhibitor (IC(50)=21 nM) with excellent in vivo activity and pharmacokinetic profile.
ESTHER : Biftu_2007_Bioorg.Med.Chem.Lett_17_3384
PubMedSearch : Biftu_2007_Bioorg.Med.Chem.Lett_17_3384
PubMedID: 17433672
Gene_locus related to this paper: human-DPP4

Title : 4-aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV - Duffy_2007_Bioorg.Med.Chem.Lett_17_2879
Author(s) : Duffy JL , Kirk BA , Wang L , Eiermann GJ , He H , Leiting B , Lyons KA , Patel RA , Patel SB , Petrov A , Scapin G , Wu JK , Thornberry NA , Weber AE
Ref : Bioorganic & Medicinal Chemistry Lett , 17 :2879 , 2007
Abstract : A novel series of 4-aminophenylalanine and 4-aminocyclohexylalanine derivatives were designed and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4). The phenylalanine series afforded compounds such as 10 that were potent and selective (DPP-4, IC(50)=28nM), but exhibited limited oral bioavailability. The corresponding cyclohexylalanine derivatives such as 25 afforded improved PK exposure and efficacy in a murine OGTT experiment. The X-ray crystal structure of 25 bound to the DPP-4 active site is presented.
ESTHER : Duffy_2007_Bioorg.Med.Chem.Lett_17_2879
PubMedSearch : Duffy_2007_Bioorg.Med.Chem.Lett_17_2879
PubMedID: 17350841
Gene_locus related to this paper: human-DPP4

Title : Design, synthesis, and biological evaluation of triazolopiperazine-based beta-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors - Kowalchick_2007_Bioorg.Med.Chem.Lett_17_5934
Author(s) : Kowalchick JE , Leiting B , Pryor KD , Marsilio F , Wu JK , He H , Lyons KA , Eiermann GJ , Petrov A , Scapin G , Patel RA , Thornberry NA , Weber AE , Kim D
Ref : Bioorganic & Medicinal Chemistry Lett , 17 :5934 , 2007
Abstract : Various beta-amino amides containing triazolopiperazine heterocycles have been prepared and evaluated as potent, selective, orally active dipeptidyl peptidase IV (DPP-4) inhibitors. These compounds display excellent oral bioavailability and good overall pharmacokinetic profiles in preclinical species. Moreover, in vivo efficacy in an oral glucose tolerance test in lean mice is demonstrated.
ESTHER : Kowalchick_2007_Bioorg.Med.Chem.Lett_17_5934
PubMedSearch : Kowalchick_2007_Bioorg.Med.Chem.Lett_17_5934
PubMedID: 17827003
Gene_locus related to this paper: human-DPP4

Title : 4-arylcyclohexylalanine analogs as potent, selective, and orally active inhibitors of dipeptidyl peptidase IV - Kaelin_2007_Bioorg.Med.Chem.Lett_17_5806
Author(s) : Kaelin DE , Smenton AL , Eiermann GJ , He H , Leiting B , Lyons KA , Patel RA , Patel SB , Petrov A , Scapin G , Wu JK , Thornberry NA , Weber AE , Duffy JL
Ref : Bioorganic & Medicinal Chemistry Lett , 17 :5806 , 2007
Abstract : A novel series of 4-arylcyclohexylalanine DPP-4 inhibitors was synthesized and tested for inhibitory activity as well as selectivity over the related proline-specific enzymes DPP-8 and DPP-9. Optimization of this series led to 28 (DPP-4 IC(50)=4.8 nM), which showed an excellent pharmacokinetic profile across several preclinical species. Evaluation of 28 in an oral glucose tolerance test demonstrated that this compound effectively reduced glucose excursion in lean mice.
ESTHER : Kaelin_2007_Bioorg.Med.Chem.Lett_17_5806
PubMedSearch : Kaelin_2007_Bioorg.Med.Chem.Lett_17_5806
PubMedID: 17851076
Gene_locus related to this paper: human-DPP4

Title : Optimization of 1,4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes - Liang_2007_Bioorg.Med.Chem.Lett_17_1903
Author(s) : Liang GB , Qian X , Feng D , Biftu T , Eiermann G , He H , Leiting B , Lyons K , Petrov A , Sinha-Roy R , Zhang B , Wu J , Zhang X , Thornberry NA , Weber AE
Ref : Bioorganic & Medicinal Chemistry Lett , 17 :1903 , 2007
Abstract : Following the discovery of N-acyl-1,4-diazepan-2-one as a novel pharmacophore for potent and selective DPP-4 inhibitors, optimization of this new lead with different substitution on the seven-membered ring resulted in several highly potent and selective, orally bioavailable, and efficacious DPP-4 inhibitors, such as 3R-methyl-1-cyclopropyl-1,4-diazepan-2-one derivative 9i (DPP-4 IC(50)=8.0 nM) and 3R,6R-dimethyl-1,4-diazepan-2-one derivative 14a (DPP-4 IC(50)=9.7 nM).
ESTHER : Liang_2007_Bioorg.Med.Chem.Lett_17_1903
PubMedSearch : Liang_2007_Bioorg.Med.Chem.Lett_17_1903
PubMedID: 17291750

Title : (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]tr iazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes - Edmondson_2006_J.Med.Chem_49_3614
Author(s) : Edmondson SD , Mastracchio A , Mathvink RJ , He J , Harper B , Park YJ , Beconi M , Di Salvo J , Eiermann GJ , He H , Leiting B , Leone JF , Levorse DA , Lyons K , Patel RA , Patel SB , Petrov A , Scapin G , Shang J , Roy RS , Smith A , Wu JK , Xu S , Zhu B , Thornberry NA , Weber AE
Ref : Journal of Medicinal Chemistry , 49 :3614 , 2006
Abstract : A series of beta-substituted biarylphenylalanine amides were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of type 2 diabetes. Optimization of the metabolic profile of early analogues led to the discovery of (2S,3S)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]tr iazolo[1,5-a]pyridin-6-ylphenyl)butanamide (6), a potent, orally active DPP-4 inhibitor (IC(50) = 6.3 nM) with excellent selectivity, oral bioavailability in preclinical species, and in vivo efficacy in animal models. Compound 6 was selected for further characterization as a potential new treatment for type 2 diabetes.
ESTHER : Edmondson_2006_J.Med.Chem_49_3614
PubMedSearch : Edmondson_2006_J.Med.Chem_49_3614
PubMedID: 16759103
Gene_locus related to this paper: human-DPP4

Title : Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors - Xu_2006_Bioorg.Med.Chem.Lett_16_1346
Author(s) : Xu J , Wei L , Mathvink R , Edmondson SD , Mastracchio A , Eiermann GJ , He H , Leone JF , Leiting B , Lyons KA , Marsilio F , Patel RA , Petrov A , Wu JK , Thornberry NA , Weber AE
Ref : Bioorganic & Medicinal Chemistry Lett , 16 :1346 , 2006
Abstract : anti-Substituted beta-methylphenylalanine derived amides have been shown to be potent DPP-IV inhibitors exhibiting excellent selectivity over both DPP8 and DPP9. The optimized compound exhibited good pharmacokinetic profiles in three preclinical species.
ESTHER : Xu_2006_Bioorg.Med.Chem.Lett_16_1346
PubMedSearch : Xu_2006_Bioorg.Med.Chem.Lett_16_1346
PubMedID: 16332437

Title : Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors - Xu_2006_Bioorg.Med.Chem.Lett_16_5373
Author(s) : Xu J , Wei L , Mathvink RJ , Edmondson SD , Eiermann GJ , He H , Leone JF , Leiting B , Lyons KA , Marsilio F , Patel RA , Patel SB , Petrov A , Scapin G , Wu JK , Thornberry NA , Weber AE
Ref : Bioorganic & Medicinal Chemistry Lett , 16 :5373 , 2006
Abstract : A novel series of oxadiazole based amides have been shown to be potent DPP-4 inhibitors. The optimized compound 43 exhibited excellent selectivity over a variety of DPP-4 homologs.
ESTHER : Xu_2006_Bioorg.Med.Chem.Lett_16_5373
PubMedSearch : Xu_2006_Bioorg.Med.Chem.Lett_16_5373
PubMedID: 16919457
Gene_locus related to this paper: human-DPP4

Title : (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes - Kim_2005_J.Med.Chem_48_141
Author(s) : Kim D , Wang L , Beconi M , Eiermann GJ , Fisher MH , He H , Hickey GJ , Kowalchick JE , Leiting B , Lyons K , Marsilio F , McCann ME , Patel RA , Petrov A , Scapin G , Patel SB , Roy RS , Wu JK , Wyvratt MJ , Zhang BB , Zhu L , Thornberry NA , Weber AE
Ref : Journal of Medicinal Chemistry , 48 :141 , 2005
Abstract : A novel series of beta-amino amides incorporating fused heterocycles, i.e., triazolopiperazines, were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of type 2 diabetes. (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl]-1-(2,4,5-trifluorophenyl)butan-2-amine (1) is a potent, orally active DPP-IV inhibitor (IC(50) = 18 nM) with excellent selectivity over other proline-selective peptidases, oral bioavailability in preclinical species, and in vivo efficacy in animal models. MK-0431, the phosphate salt of compound 1, was selected for development as a potential new treatment for type 2 diabetes.
ESTHER : Kim_2005_J.Med.Chem_48_141
PubMedSearch : Kim_2005_J.Med.Chem_48_141
PubMedID: 15634008
Gene_locus related to this paper: human-DPP4

Title : Discovery of potent and selective orally bioavailable beta-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors - Edmondson_2005_Bioorg.Med.Chem.Lett_15_3048
Author(s) : Edmondson SD , Mastracchio A , Duffy JL , Eiermann GJ , He H , Ita I , Leiting B , Leone JF , Lyons KA , Makarewicz AM , Patel RA , Petrov A , Wu JK , Thornberry NA , Weber AE
Ref : Bioorganic & Medicinal Chemistry Lett , 15 :3048 , 2005
Abstract : anti-Substituted biaryl beta-methylphenylalanine derived amides have been shown to be potent DPP-IV inhibitors that suffer from suboptimal selectivity and pharmacokinetics. This letter describes the substitution of the beta-methyl substituent with beta-polar substituents, culminating in the discovery of a beta-dimethylamide substituted phenylalanine derivative with an excellent potency, selectivity, and pharmacokinetic profile.
ESTHER : Edmondson_2005_Bioorg.Med.Chem.Lett_15_3048
PubMedSearch : Edmondson_2005_Bioorg.Med.Chem.Lett_15_3048
PubMedID: 15908206

Title : 4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors - Parmee_2004_Bioorg.Med.Chem.Lett_14_43
Author(s) : Parmee ER , He J , Mastracchio A , Edmondson SD , Colwell L , Eiermann G , Feeney WP , Habulihaz B , He H , Kilburn R , Leiting B , Lyons K , Marsilio F , Patel RA , Petrov A , Di Salvo J , Wu JK , Thornberry NA , Weber AE
Ref : Bioorganic & Medicinal Chemistry Lett , 14 :43 , 2004
Abstract : Substituted 4-amino cyclohexylglycine analogues were evaluated for DP-IV inhibitory properties. Bis-sulfonamide 15e was an extremely potent 2.6 nM inhibitor of the enzyme with excellent selectivity over all counterscreens. 2,4-difluorobenzenesulfonamide 15b and 1-naphthyl amide 16b, however, combined an acceptable in vitro profile with good pharmacokinetic properties in the rat, and 15b was orally efficacious at 3 mpk in an OGTT in lean mice.
ESTHER : Parmee_2004_Bioorg.Med.Chem.Lett_14_43
PubMedSearch : Parmee_2004_Bioorg.Med.Chem.Lett_14_43
PubMedID: 14684294